Glimepiride 0.5 mg + Voglibose 0.2 mg + Metformin SR 500 mg | Steris Healthcare

Type 2 diabetes is a chronic metabolic condition that affects how the body regulates blood glucose. Effective management often requires a combination of medication, balanced nutrition, physical activity and regular monitoring. When one medicine does not provide adequate glucose control, a healthcare professional may consider combining medicines that act through different mechanisms.

Glimepiride 0.5 mg, Voglibose 0.2 mg and Metformin Hydrochloride (SR) 500 mg tablets combine three oral antidiabetic agents to help manage blood glucose levels in appropriately selected adults with type 2 diabetes mellitus.

Steris Healthcare is the brand name to use when discussing the requested pharmaceutical product. Before publication or procurement, confirm the exact product name, manufacturer, approved composition and availability using current official product documentation.

This article explains the composition, indications, mechanism of action, benefits, clinical evidence, potential side effects, dosage considerations and precautions associated with this triple-drug combination. It is intended for educational purposes and does not replace a doctor's prescription.

 Composition of Glimepiride, Voglibose and Metformin SR Tablets

The requested formulation contains three active pharmaceutical ingredients, each contributing a different glucose-lowering action.

1. Glimepiride 0.5 mg

Glimepiride belongs to the sulfonylurea class of antidiabetic medicines. It stimulates insulin release from pancreatic beta cells, helping the body lower elevated blood glucose levels.

Because it can cause hypoglycaemia, its use requires appropriate dose selection, regular meals and monitoring as advised by a healthcare professional.

2. Voglibose 0.2 mg

Voglibose is an alpha-glucosidase inhibitor. It slows the digestion and absorption of certain carbohydrates in the intestine, helping reduce the rise in blood glucose after meals.

Its effects are particularly relevant to postprandial blood glucose, which is the glucose level measured after eating.

3. Metformin Hydrochloride (SR) 500 mg

Metformin is a biguanide antidiabetic medicine. It primarily reduces glucose production in the liver and improves the body's response to insulin.

The sustained-release (SR) formulation is designed to release the medicine gradually. The tablet should be taken according to its product-specific instructions and should not be crushed or chewed unless the approved product information explicitly permits this.

The complete excipient list, including inactive ingredients and coating materials, should be verified from the current product label.

 How Does Glimepiride 0.5 mg, Voglibose 0.2 mg and Metformin SR 500 mg Work?

This triple combination targets different processes involved in type 2 diabetes. By addressing insulin secretion, glucose production and carbohydrate absorption, the ingredients may provide complementary glucose-lowering effects when prescribed appropriately.

Mechanism of action

• Glimepiride: Stimulates insulin secretion from pancreatic beta cells by acting on ATP-sensitive potassium channels. This helps lower blood glucose but can also cause hypoglycaemia.
• Voglibose: Inhibits intestinal alpha-glucosidase enzymes, delaying carbohydrate breakdown and reducing the rate at which glucose enters the bloodstream after meals.
• Metformin SR: Reduces hepatic glucose production and improves insulin sensitivity, helping the body regulate blood glucose more effectively.

The combination is designed to address multiple contributors to hyperglycaemia rather than relying on a single mechanism.

The actual response depends on factors such as diabetes duration, pancreatic function, dietary habits, kidney and liver health, medication adherence and other treatments.

 Why Is This Triple Combination Important in Type 2 Diabetes?

Type 2 diabetes involves several metabolic abnormalities. Some patients experience elevated fasting glucose, while others also have significant rises in glucose after meals.

Combining medicines with complementary mechanisms may help address these different patterns when treatment with a single agent or a dual combination is insufficient.

For appropriately selected patients, the combination may support better glycaemic control alongside a personalised diet and physical activity plan. However, three-drug therapy is not automatically suitable for every person with diabetes.

In India, where type 2 diabetes is a major healthcare concern, treatment decisions should be based on blood glucose measurements, HbA1c results, comorbidities, kidney function and individual treatment goals. Patients in Jaipur and other cities should consult a qualified physician or diabetologist before starting or changing diabetes medication.

 Indications of Glimepiride 0.5 mg, Voglibose 0.2 mg and Metformin SR 500 mg Tablets

The individual ingredients are used to improve blood glucose control in type 2 diabetes. A fixed-dose combination may be prescribed to adults for whom the clinician considers all three agents appropriate.

Potential treatment considerations include:

• Blood glucose levels remaining above the individual's target despite existing treatment.
• A need to address both fasting and post-meal glucose elevations.
• The need for complementary mechanisms of glucose lowering.
• A clinician's assessment that a fixed-dose combination is suitable for the patient's overall treatment plan.

The precise approved indication for the specific product must be confirmed from its current prescribing information.

This combination is not intended to treat type 1 diabetes or diabetic ketoacidosis. It should not be used for self-treatment of high blood glucose without medical assessment.

 Key Benefits of the Triple Combination Diabetes Medicine

 What Are the Benefits?

1. Multiple mechanisms of glucose control

The three ingredients work through different pathways, potentially improving glucose control in appropriately selected patients.

2. Support for fasting glucose management

Metformin reduces hepatic glucose production, while glimepiride stimulates insulin release. Together, these actions may help lower elevated blood glucose.

3. Support for post-meal glucose management

Voglibose delays carbohydrate absorption, helping reduce rapid increases in blood glucose following meals.

4. Potentially convenient administration

A fixed-dose combination may reduce the number of separate tablets a patient needs to take compared with taking each ingredient individually. Convenience depends on the prescribed regimen and the suitability of the fixed strengths.

5. Complementary glucose-lowering effects

The combination addresses several aspects of glucose regulation. Its benefits must be balanced against the risks of hypoglycaemia, gastrointestinal adverse effects and other medicine-specific precautions.

These are potential therapeutic benefits, not guarantees of treatment success. The medicine does not replace healthy eating, physical activity, glucose monitoring or regular medical follow-up.

 Efficacy and Clinical Evidence

Clinical evidence for glimepiride, voglibose and metformin combinations includes observational research and clinical studies of related triple-drug formulations.

A multicentre observational study published in 2024 examined the prescribing patterns of glimepiride, metformin and voglibose combinations in 8,587 adults with type 2 diabetes across India. It documented the use of these combinations in routine clinical practice. Because the study was observational, it primarily describes prescribing patterns and does not establish that one formulation is superior to another.

A Phase IV randomised study published in 2026 evaluated glimepiride, voglibose and extended-release metformin against two-drug combinations in adults whose diabetes was inadequately controlled with metformin. The study reported greater HbA1c reductions with the triple combination over 12 and 24 weeks compared with the comparator combinations.

Importantly, that trial studied triple combinations containing glimepiride 1 mg or 2 mg with voglibose 0.2 mg and extended-release metformin 500 mg. Its findings should not be treated as direct proof of equivalent efficacy or safety for the exact 0.5 mg glimepiride formulation discussed here.

 Side Effects of Glimepiride, Voglibose and Metformin SR Tablets

As with other antidiabetic medicines, this combination can cause adverse effects. Their frequency and severity vary according to the patient, dose, diet, kidney function and concurrent medications.

Potential side effects include:

• Hypoglycaemia: Low blood glucose, particularly associated with glimepiride.
• Gastrointestinal discomfort: Bloating, abdominal discomfort, diarrhoea or flatulence, particularly associated with voglibose and metformin.
• Nausea: May occur, especially during treatment initiation or dose changes.
• Reduced appetite: Some patients may experience appetite changes or gastrointestinal intolerance.
• Vitamin B12 deficiency: Long-term metformin use can reduce vitamin B12 levels in some patients.

Patients should report persistent symptoms to their healthcare professional rather than independently changing the dose.

 Serious Side Effects of the Triple Combination

Severe hypoglycaemia: Warning signs may include sweating, shaking, dizziness, intense hunger, confusion, unusual behaviour, seizures or loss of consciousness. Severe symptoms require emergency assistance.

Lactic acidosis: This is a rare but serious complication associated with metformin. Risk increases in certain circumstances, including severe kidney impairment, significant dehydration, severe infection, hypoxia and some other acute illnesses. Unusual severe weakness, muscle pain, breathing difficulty, abdominal symptoms or reduced alertness require urgent medical assessment.

Liver-related concerns: Patients with significant liver disease need medical assessment before treatment, as it may affect the suitability of the combination.

Allergic reactions: Facial swelling, difficulty breathing or a severe widespread reaction requires emergency medical attention.

Patients should receive clear instructions on recognising and managing hypoglycaemia. They should also know when acute illness, dehydration or planned surgery or contrast imaging requires contacting their treating clinician about metformin.

 Available Substitutes for Glimepiride, Voglibose and Metformin SR Tablets

Substitution depends on the individual's glucose-control needs, kidney function, treatment history, adverse effects and the approved products available locally.

A doctor or pharmacist may consider:

• Another authorised product containing the same three active ingredients and matching strengths.
• Appropriate two-drug combinations, such as metformin with glimepiride or metformin with voglibose, if clinically suitable.
• Other antidiabetic medicines from different classes when the patient's medical profile supports their use.

These options are not automatically interchangeable. A product containing a different glimepiride strength or a different metformin release formulation may have different dosing and safety implications.

Patients should not substitute, combine or discontinue diabetes medicines without professional guidance.

 Dosage Guidelines for Glimepiride 0.5 mg, Voglibose 0.2 mg and Metformin SR 500 mg

The appropriate dosage must be determined by the prescribing clinician. It depends on the patient's blood glucose results, current medication regimen, renal function, meal schedule and risk of hypoglycaemia.

There is no universally appropriate dosing schedule for every patient using this combination.

General precautions include:

• Take the medicine exactly as prescribed and follow the product-specific instructions concerning meals.
• Take glimepiride-containing treatment with particular attention to regular meals and the risk of low blood glucose.
• Swallow the sustained-release tablet as instructed; do not crush or chew it unless the approved label specifically permits this.
• Do not take an extra dose to compensate for a missed dose without professional advice.
• Monitor blood glucose as recommended and attend scheduled HbA1c and kidney-function reviews.

If a meal is missed, the patient is vomiting, or food intake is substantially reduced, the risk of hypoglycaemia may change. Follow the clinician's sick-day and medication instructions.

 Precautions and Warnings

Kidney function: Metformin requires careful assessment of kidney function. The combination may be unsuitable in severe renal impairment, and the appropriate treatment must be determined by a clinician.

Liver disease: Significant liver disease can influence treatment suitability and may increase the risk associated with metformin.

Older adults: Older patients may have greater vulnerability to hypoglycaemia, dehydration and reduced kidney function. Regular medication reviews are important.

Pregnancy and breastfeeding: Diabetes treatment may need to be changed during pregnancy or breastfeeding. A qualified clinician should determine the appropriate medicine.

Alcohol: Alcohol may increase certain risks associated with metformin and can contribute to hypoglycaemia in patients taking sulfonylureas. Discuss alcohol use with the prescribing clinician.

Other medicines: Tell the doctor about all prescription medicines, supplements and non-prescription products. Some medicines can affect blood glucose or increase the risk of adverse effects.

Surgery and contrast procedures: Inform the healthcare team that you take metformin before surgery or imaging procedures involving iodinated contrast. Temporary interruption may be necessary in certain circumstances, depending on kidney function and the procedure.

 Steris Healthcare and Pharmaceutical Buyer Considerations

For pharmaceutical buyers, pharmacists and healthcare institutions in India, product evaluation should include verification of the exact composition, dosage form, approved product information and legitimate supply arrangements.

When assessing a product associated with Steris Healthcare, confirm:

• The manufacturer's current product documentation.
• The stated strengths of glimepiride, voglibose and metformin SR.
• Batch traceability, packaging integrity and expiry information.
• Applicable regulatory authorisation and distribution details.
• Current availability and commercial terms through an authorised supplier.

Do not assume that a particular formulation, brand or pack size is available without confirmation. Patients should obtain the medicine through legitimate pharmacy channels and use it only under appropriate medical supervision.

Conclusion

Glimepiride 0.5 mg, Voglibose 0.2 mg and Metformin Hydrochloride (SR) 500 mg tablets combine three antidiabetic agents that act through complementary mechanisms. Glimepiride stimulates insulin secretion, voglibose slows carbohydrate absorption, and metformin reduces hepatic glucose production while improving insulin sensitivity.

Clinical research involving related triple-drug combinations supports their potential role in improving glycaemic control in selected adults with type 2 diabetes. However, evidence from different strengths should not automatically be applied to this exact formulation.

Steris Healthcare is the brand name specified for this SEO article. Before publishing product-specific claims, verify the manufacturer's current documentation and the product's approved details.

Successful diabetes management depends on individualised prescribing, regular monitoring, a balanced diet, physical activity and awareness of adverse effects. Patients should consult their doctor before starting, changing or replacing any antidiabetic medicine.

Frequently Asked Questions 

1. What is Glimepiride 0.5 mg, Voglibose 0.2 mg and Metformin SR 500 mg used for?

It is a triple-drug formulation intended to help manage blood glucose in selected adults with type 2 diabetes when the combination is considered appropriate by their healthcare professional.

2. What is the composition of this diabetes medicine?

The stated composition is glimepiride 0.5 mg, voglibose 0.2 mg and metformin hydrochloride sustained-release 500 mg per tablet. Verify the current product label for complete composition details.

3. How does this triple combination work?

Glimepiride stimulates insulin secretion, voglibose slows carbohydrate digestion and absorption, and metformin reduces glucose production in the liver while improving insulin sensitivity.

4. What are the benefits of this combination?

It may help improve fasting and post-meal glucose control by targeting different mechanisms involved in type 2 diabetes. Individual benefits depend on the patient's condition and treatment response.

5. Can this medicine cause low blood sugar?

Yes. Glimepiride can cause hypoglycaemia, particularly when meals are delayed or missed, during excessive exercise, or when used with other glucose-lowering medicines. Follow your clinician's guidance on recognising and treating low blood glucose.

6. What are the common side effects?

Possible side effects include hypoglycaemia, nausea, abdominal discomfort, diarrhoea, bloating and flatulence. Long-term metformin treatment can also contribute to vitamin B12 deficiency.

7. Is this medicine suitable for people with kidney disease?

Not everyone with kidney disease can safely use this combination. Metformin requires kidney-function assessment, and treatment may be contraindicated in severe renal impairment. Consult a qualified clinician.

8. Can this combination replace metformin alone?

A doctor may consider combination treatment when metformin alone does not provide adequate glucose control. The decision depends on HbA1c, glucose measurements, other medical conditions and the risk of adverse effects.

9. What is the recommended dosage?

The dosage must be individualised by the prescribing clinician. Follow the exact prescription and product-specific instructions rather than copying a dosage used for another patient or brand.

10. Where can healthcare buyers find this medicine in India?

Healthcare buyers should contact legitimate pharmaceutical suppliers and verify the product's exact composition, manufacturer documentation, regulatory status and availability before procurement.